HL Genomics KRX:0156T0KOSDAQ
에이치엘지노믹스 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days1
Articles tracked0since Sep 11
In Q2 2026, HL Genomics reported revenue of ₩6.6bn, up 6.2% year on year, and operating profit of ₩2.1bn. HL Genomics (에이치엘지노믹스) appeared in 0 Korean news articles and 1 DART filing over the past seven days.
Filing signals Op. margin 20%+ Asset deal Screener
HL Genomics quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩6.6bn | +6.2% | ₩2.1bn margin 32.0% | ₩1.8bn |
| Q2 2025 | ₩6.2bn | – | ₩2.0bn margin 31.9% | ₩1.8bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
HL Genomics top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest HL Genomics news Korean headlines
No articles yet.